(MedPage Today) — CHICAGO — Neoadjuvant nivolumab (Opdivo) plus chemotherapy significantly improved overall survival (OS) compared with chemotherapy alone for patients with resectable non-small cell lung cancer (NSCLC), the phase III CheckMate…
Source link : https://www.medpagetoday.com/meetingcoverage/asco/115875
Author :
Publish date : 2025-06-03 16:38:00
Copyright for syndicated content belongs to the linked Source.
